Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate Cancer with Combination Treatment Than with ADT Alone
Findings from a meta-analysis of two randomised controlled phase III studies of the STAMPEDE platform protocol